Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GammaDelta Therapeutics
London, England, United Kingdomgammadeltatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Advanced a first program into Phase 1 clinical trials for cancer using allogeneic γδ T cells. The company’s approach was considered differentiated and promising for both solid and blood cancers. No detailed efficacy results publicly available as of acquisition.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Allogeneic cell therapies based on gamma delta (γδ) T cells, specifically Vδ1+ T cells
- Industry
- Biotech
02
Partnerships
Takeda Pharmaceutical Company Limited—strategic collaboration and eventual acquirer.Abingworth LLP—major investor and collaborator.
Beyond the preview
Go deeper on GammaDelta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GammaDelta Therapeutics.